In our first cohort (34 FFPE samples), we purposefully included 2 tumor samples (samples 32 and 33 in Table 3) with ERBB2 amplification but high MAPD scores (0.45 and 0.46, respectively) for orthogonal testing. This evidence concerns the gene ERBB2 and neoplasm.